NCT00535054已完成不适用
An Open Study to Assess the Safety and Patients' Satisfaction Tears Again* in the Treatment of Dry Eye Symptoms
Trima, Israel Pharmaceutical Products1 个研究点 分布在 1 个国家目标入组 125 人开始时间: 2007年9月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 125
- 试验地点
- 1
- 主要终点
- Schirmer Test, Lissamine Green Test and BUT.
研究概览
简要总结
The purpose of this study is to determine safety and patients' satisfaction when using Tears Again to treat Dry Eye Symptoms.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 25 Years 至 85 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Suffer from at least two of the following ocular symptoms: burning, stinging, excessive tearing, dryness, grittiness, foreign body sensation ( including patients suffering from blepharitis).
- •Use artificial tears or any other treatment for these symptoms three or more times a day.
排除标准
- •Known hypersensitivity to Phenoxyethanol.
- •Pregnant and lactating women.
- •Receive other ophthalmic medication (except for eyelid hygiene preparations).
- •Graft-versus-host disease patients.
- •Participated during the last month in another clinical trial.
研究组 & 干预措施
Tears Again
Experimental
All subjects shall be treated with Tears Again.
干预措施: Tears Again (Drug)
结局指标
主要结局
Schirmer Test, Lissamine Green Test and BUT.
时间窗: On enrollment and one month later.
次要结局
- Questionaire(One, three and four weeks after treatment commencement.)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
A Pilot Study of the TearCare System in Adults With Dry Eye DiseaseDry EyeNCT03006978Sight Sciences, Inc.24
终止
不适用
ARISTOCRAT-A Randomized Controlled Trial Evaluating Closure Following Access With the AXERA (Device Name) 2 Access SystemCoronary Artery DiseaseNCT02061696Frank Saltiel39
已完成
1 期
Trial of Active Immunotherapy With OBI-833 (Globo H-CRM197) in Advanced/Metastatic Gastric, Lung, Colorectal or Breast Cancer SubjectsMetastatic Gastric CancerMetastatic Colorectal CancerMetastatic Lung CancerMetastatic Breast CancerNCT02310464OBI Pharma, Inc25
终止
3 期
Study of Ataluren (PTC124) in Cystic FibrosisCystic FibrosisNCT02107859PTC Therapeutics61
已完成
2 期
Investigation of the Safety, Tolerability and Potential Therapeutic Effects of JNJ-40411813 in Patients With SchizophreniaSchizophreniaNCT01323205Janssen Research & Development, LLC100